Back to mobile site

JPMorgan Resumes Legend Biotech Corp. (LEGN) at Neutral

July 13, 2026 3:13 AM EDT Send to a Friend
JPMorgan analyst Jessica Fye resumes coverage on Legend Biotech Corp. (NASDAQ: LEGN) with a Neutral rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login